"We are honored to have Jim as an advisor to Arena. In a rapidly evolving industry, and especially in dynamic and challenging times, we rely on our Board and advisors to challenge us to make the best possible decisions for all of our stakeholders," said Amit D. Munshi, President and Chief Executive Officer of Arena. "With his impressive history of successfully building and growing companies globally, Jim's insights will be critical as we continue to scale a vibrant, sustainable business."
"I am excited about Arena's vision and pipeline," said James C. Mullen. "I look forward to working with Amit and the team - providing guidance as they navigate toward bringing these important medicines to the market."
Mr. Mullen has more than 30 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, Mr. Mullen served as Chief Executive Officer of Patheon N.V., a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Before joining Patheon, Mr. Mullen served as Chief Executive Officer and President at Biogen, Inc., one of the world's largest biotechnology companies. Prior to being named Chief Executive Officer, Mr. Mullen held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Before joining Biogen, he held several manufacturing and engineering positions at SmithKline Beecham (now GlaxoSmithKline plc). Mr. Mullen also serves on the Board of Directors of Insulet Corporation and as Chairman of Board of Directors at Vicarius Pharma AG. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization (BIO). Mr. Mullen holds a B.S in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.
About Arena Pharmaceuticals
Arena Pharmaceuticals is uniquely positioned to develop best-in-disease medicines with optimized efficacy and safety for patients globally. Our drive to deliver a robust pipeline of novel, transformational medicines is grounded in two decades of world class G-protein-coupled receptor (GPCR) discovery research.
It is the breadth and depth of our portfolio, prioritization of drug development to meet unmet patient needs, strong financial health and growing, bold-thinking world-class team that gives Arena the ingredients and passion to build a sustainable, vibrant next-generation pharmaceutical company.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements may be identified by words such as "will," "continue to," "look forward to," "uniquely positioned to," and "drive to," and include, without limitation, statements about Mr. Mullen's expected contributions; the potential of Arena's drug candidates, including to be approved and brought to market, be best-in-disease, have optimized efficacy and safety, and be delivered to patients globally; and Arena's position, drive, portfolio, prioritization, financial position, team, and building of the company. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: clinical trials and other studies may not proceed at the time or in the manner expected or at all; the timing and outcome of research, development and regulatory review is uncertain, and Arena's drug candidates may not advance in development or be approved for marketing; Arena may need additional funds to advance all of its programs, and you and others may not agree with the manner Arena allocates its resources; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; risks related to unexpected or unfavorable new data; and other risks related to developing and commercializing drugs; as well as those factors disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
Arena Media Contact:
SOURCE Arena Pharmaceuticals, Inc.